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https://doi.org/1Objective: The aim of this work was to study the association of high-sensitivity troponin T (hsTnT) with
incident heart failure (HF), and implications for its use in prediction models.
Methods and Results: In the British Regional Heart Study, 3852 men aged 6079 years without baseline
HF (3165 without baseline chronic heart disease) were followed for a median of 12.6 years, during which
295 incident cases of HF occurred (7.7%). A 1-SD increase in log-transformed hsTnT was associated with
a higher risk of incident HF after adjusting for classic risk factors (hazard ratio [HR] 1.58, 95% confidence
interval [CI] 1.421.77) and after additional adjustment for N-terminal proB-type natriuretic peptide
(NT-proBNP; HR 1.34, 95% CI 1.191.52). The strength of the association between hsTnT and incident
HF did not differ by strata of other risk factors. An hsTnT concentration of <5 ng/L had a sensitivity of
99.7% (95% CI 98.1%99.9%) and a specificity of 3.4% (95% CI 2.8%4.0%). A risk-prediction model
including classic risk factors and NT-proBNP yielded a C-index of 0.791, but addition of hsTnT did not fur-
ther improve prediction (P = .28).
Conclusions: Elevated hsTnT is consistently associated with risk of HF in older men. HF occurred rarely
over 12 years when baseline hsTnT was below the limit of detection. hsTnT measurement, however, does
not improve HF prediction in a model already containing NT-proBNP. (J Cardiac Fail 2019;25:230237)
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230The lifetime risk of developing heart failure (HF) of a
person aged >40 years in the general population is esti-
mated to be 20%, and although therapies for HF are improv-
ing, once diagnosed, 14% of patients die in the first
6 months.1,2 The etiology of HF varies from country to
country, although the majority of cases are attributed to
hypertension and coronary artery disease.3 As such, it is
well understood that onset of HF is a common occurrence
after clinically diagnosed myocardial infarction.4 However,
it is possible that recurrent subclinical episodes of cardiac
ischemia and cardiomyocyte necrosis lead to HF.5
Circulating cardiac troponin levels are excellent bio-
markers of myocardial injury, including ischemia.6,7 As
such, several studies have used high-sensitivity troponin
T (hsTnT) or high-sensitivity troponin I assays as a proxy
for subclinical myocardial damage in investigating causes
of HF.812 However, it is not clear from the existing litera-
ture what information troponin measurement adds to
N-terminal proB-type natriuretic peptide (NT proBNP).
NT-proBNP integrates information about cardiac loading,
structure, and function, the heart rhythm, renal function,
Troponin Tand Incident Heart Failure  Welsh et al 231and possibly other neurohumoral pathways. Because natri-
uretic peptides are increasingly part of the clinical defini-
tion of HF13 and are routinely measured during the
diagnostic evaluation of patients with suspected HF, NT-
proBNP is a strong candidate biomarker for prediction
models in people without HF. It is also possible that tropo-
nin will also be valuable in such predictive models. A key
question is not only whether continuous troponin levels pre-
dict HF, but also whether low troponin levels, indicating an
absence of myocardial injury, preclude occurrence of HF.
We therefore used the British Regional Heart study to
test the hypothesis that hsTnT is associated with risk of
incident HF in older men with and without clinical evidence
of baseline coronary heart disease (CHD), adjusting for
incident CHD during follow-up. We also examined whether
the measurement of hsTnT usefully predicts risk of incident
HF beyond the measurement of NT-proBNP.Methods
British Regional Heart Study
The British Regional Heart Study was a socioeconomi-
cally representative prospective study of 7735 men aged
4059 years and of predominantly white European ethnic-
ity (>99%), drawn from 1 general practice in each of 24
British towns, who were screened from 1978 to 1980.14 In
19982000, surviving men aged 6079 years were invited
for a 20th-year follow-up examination, on which the present
analyses were based.15,16 Ethical approval was obtained
from all relevant local Research Ethics Committees, and
informed consent had been obtained from the subjects. Fol-
low-up was possible for 99% of the cohort. All of the men
completed a mailed questionnaire providing information on
their lifestyle and medical history, had a physical examina-
tion, and provided a fasting blood sample. Physical activity,
alcohol consumption, and an index of socioeconomic depri-
vation were derived and coded as detailed elsewhere.17
Twelve-lead electrocardiograms were recorded with the use
of a Siemens Sicard 460 instrument and analyzed according
to Minnesota Coding definitions at the University of Glas-
gow electrocardiography core laboratory. Atrial fibrillation
was defined according to Minnesota Codes 8.3.1 and 8.3.3
on the baseline electrocardiography. The men were asked
whether a doctor had ever told them that they had myocar-
dial infarction (MI), HF, or stroke; details of their medica-
tions, including use of statins, were recorded at the
examination. Predicted glomerular filtration rate (eGFR)
was estimated from serum creatinine: eGFR = 186£ (crea-
tinine)¡1.154£ (age)¡0.203.
In all, 4252 men (77% of the survivors) attended the
19982000 examination; 130 men who experienced HF
before the baseline examination were excluded; 79 men
with missing information on history of MI or angina were
also excluded; and an additional 191 with a missing hsTnT
measurements were excluded, leaving 3852 men included
in the analysis.Baseline CHD was defined as previous self-reported,
doctor-diagnosed, MI or angina, or MI identified during
review of medical records as part of the prospective study;
in this way, 687 men were defined as having evidence of
CHD at baseline.
Evidence of HF was obtained by reports from primary
care physicians supplemented by biennial reviews of medi-
cal records (including correspondence). Incident HF was
based on a confirmed doctor’s diagnosis of HF from pri-
mary care records and where possible, verified using details
of available clinical information from primary and second-
ary care records, as well as from death certificates (ICD-9
code 428).16
Biomarker Measurement
NT-proBNP and hsTnT were measured in plasma sam-
ples from both studies on an automated clinically validated
immunoassay analyzer (e411; Roche Diagnostics, Burgess
Hill, United Kingdom) using the manufacturers calibrators
and quality control reagents. The limit of detection was
5 ng/L for NT-proBNP, and the limit of blank was 3 ng/L
for hsTnT. We defined “low” hsTnT as the manufacturer’s
limit of detection (5 ng/L). Quality control materials over
2 levels for each biomarker ran from 4.4% to 7.7%.
Statistics
Eligible men were divided into equal tertiles based on the
hsTnT distribution. Skewed continuous variables were log-
transformed to approximate normality for parametric tests.
Comparisons of baseline characteristics between the HF
outcome groups (stratified by baseline CHD status) were
performed with the use of the x2 test for categoric variables
and t test for continuous variables; 95% confidence inter-
vals for single proportions were derived with the use of the
Jeffrey method.
Kaplan-Meier curves and the log-rank test were used to
evaluate differences in HF rates for the hsTnT tertiles. Mul-
tiple imputation with the use of chained equations was used
to generate 10 datasets with complete data.18 The imputa-
tion model included hsTnT, age, cardiovascular disease
(CVD), diabetes, incident HF (none missing), smoking
(4 missing), index of deprivation (6 missing), atrial fibrilla-
tion (9 missing), heart rate (10 missing), systolic blood
pressure (17 missing), body mass index (BMI; 17 missing),
C-reactive protein (CRP; 31 missing), eGFR (35 missing),
total cholesterol (38 missing), glucose (39 missing), forced
expiratory volume in 1 second (FEV1; 40 missing), blood
pressure medications (49 missing), alcohol use (57 miss-
ing), high-density lipoprotein (HDL) cholesterol (61 miss-
ing), physical activity (138 missing), and NT-proBNP (272
missing). Cox proportional hazards models were generated
using the “mi estimate” command in Stata. The hazard ratio
(HR) and 95% confidence intervals (CIs) of incident HF per
a 1-SD increase in log-transformed hsTnT was estimated
with the use of these models. Models adjusted for classic
risk factors, with the maximally adjusted model including
Table 1. Distribution of Risk Factors at Baseline Comparing
Those Who Experienced HF During Follow-Up With Those Who
Did Not
Risk Factor
No Incident HF
(n = 3557)
Incident HF
(n = 295) P Value
Age, y 68.5 (5.5) 70.5 (5.4) .001
BMI, kg/m2 26.8 (3.6) 27.8 (3.9) .001
Waist
circumference, cm
96.7 (10.4) 99.7 (11.2) .001
Smoking .42
Never 1048 (29.5%) 79 (26.8%)
Ex 2039 (57.4%) 181 (61.4%)
Current 466 (13.1%) 35 (11.9%)
FEV1, L 2.62 (0.65) 2.40 (0.68) .001
SBP, mmHg 149.1 (24.0) 152.2 (25.2) .04
DBP, mmHg 85.4 (11.1) 84.8 (11.0) .43
Heart rate, beats/min 65.5 (12.5) 67.6 (13.7) .006
Total cholesterol, mmol/L 6.02 (1.07) 5.90 (1.12) .08
HDL cholesterol, mmol/L 1.32 (0.34) 1.29 (0.34) .14
Glucose, mmol/L 5.99 (1.79) 6.30 (2.55) .006
Physical activity .03
Inactive 360 (10.5%) 35 (12.3%)
Occasionallight 1424 (41.5%) 127 (44.6%)
Moderatevigorous 1645 (48.0%) 123 (43.2%)
Alcohol .79
None 347 (9.9%) 32 (11.2%)
Occasionallight 2469 (70.5%) 205 (69.7%)
Moderateheavy 688 (19.6%) 54 (19.1%)
Diabetes 232 (6.5%) 33 (11.2%) .002
Atrial fibrillation 105 (3.0%) 30 (10.2%) <.001
Statin 212 (6.0%) 25 (8.5%) .084
Blood pressure
medication
1056 (30.1%) 139 (47.8%) <.001
IMD, score 20.2 (14.7) 20.6 (14.7) .66
eGFR, ml/min/1.73m2 72.8 (12.6) 70.1 (13.4) <.001
CRP, mg/L 1.54 (0.813.33) 2.16 (1.044.18) <.001
NT-proBNP, pg/ml 85 (44173) 231 (102577) <.001
hsTnT, ng/L 11.5 (8.715.6) 15.5 (11.020.1) <.001
Values are presented as mean (SD), n (%), or median (interquartile
range).
BMI, body mass index; CRP, C-reactive protein; DBP, diastolic blood
pressure; eGFR, estimated glomerular filtration rate; FEV1, forced expira-
tory volume in 1 second; HDL, high-density lipoprotein; HF, heart failure;
hsTnT, high-sensitivity troponin T; IMD, index of multiple deprivation;
NT-proBNP, N-terminal proB-type natriuretic peptide; SBP, systolic
blood pressure.
232 Journal of Cardiac Failure Vol. 25 No. 4 April 2019the variables age, smoking, total cholesterol, HDL choles-
terol, systolic blood pressure, index of multiple deprivation
(IMD), BMI, any diabetes, eGFR, blood pressure medica-
tion, statin use, heart rate, physical activity, FEV1, alcohol
consumption, CRP, and NT-proBNP. Models also included
a time-varying term adjusting for nonfatal MI that occurred
during the follow-up. Maximally adjusted models were also
tested for evidence of interaction, stratified by baseline
covariates of interest. The assumption of a linear relation-
ship between hsTnT and risk of HF was supported by
restricted cubic spline analysis.
To test clinical prediction of incident HF, C-indexes were
calculated in the imputed datasets, accounting for censor-
ing, with the use of a range of different prediction strategies
(with or without hsTnT). Prediction models included model
A) age, baseline CHD, cholesterol, HDL cholesterol, sys-
tolic blood pressure, IMD, BMI, smoking, diabetes, eGFR,
blood pressure medication, statin use, heart rate, glucose,
physical activity, FEV1, alcohol use, atrial fibrillation;
model B) model A plus NT-proBNP; model C) model B
plus hsTnT; and model D) age and NT-proBNP only.
Increased concordance was tested by comparing the
C-index of each model with every other one.
The C-statistic has been criticized for insensitivities to
changes in clinical decisions across treatment thresholds
defined by risk prediction. The categoric net reclassification
index (NRI) estimates correct changes in clinical classifica-
tion across risk thresholds. However, risk score thresholds
are currently not used to make treatment decisions to pre-
vent HF. Therefore, we used a continuous net reclassifica-
tion index (NRI), to compare model C with model B in one
imputed dataset. NRI is based on improvements in classifi-
cation across integer-percentage risk thresholds, thus avoids
making arbitrary decisions about defining clinically rele-
vant risk categories.19 We also calculated the integrated dis-
crimination improvement index (IDI), a category-free
comparative measure of the clinical validity of a new risk
score.20
All analyses were performed in Stata (version 14.2) and
R (version 3.3.1, with the use of the survIDINRI package
and 5000 bootstrap samples to generate confidence intervals
for the NRI and IDI).
Results
Classic Risk Factors
During a median follow-up period of 12.6 years (inter-
quartile range [IQR] 7.913.4 y), there were 295 incident
cases of HF in the whole cohort (n = 3852; incidence 7.7%),
including 201 incident cases (6.4%) in those without base-
line CHD (n = 3165) and 94 incident cases (13.7%) in those
with baseline CHD (n = 687; P < .001). Those who experi-
enced HF during follow-up were generally older, had higher
BMI and waist circumference, were more likely to have
diabetes, had lower FEV1 and eGFR, had higher heart rate,
were more likely to be on blood pressurelowering
medication and to have atrial fibrillation and higher CRP(Table 1). hsTnT was slightly higher in those with baseline
CHD compared with those without: median 12.9 ng/L (IQR
9.918.2) vs 11.4 ng/L (8.615.6); P < .001. NT-proBNP
was also higher in those with clinical evidence of
baseline CHD compared to those without: median 180 ng/L
(88416) vs 79 ng/L (41158); P < .001.hsTnT and Incident HF
Kaplan-Meier curves show that over the follow-up time,
baseline hsTnT concentration (as thirds of the distribution)
was strongly associated with risk of incident HF in both
those with and without baseline CHD (log rank P < .001
for both; Fig. 1).
In adjusted models, the association of log-transformed
hsTnT with HF was linear. In all participants, a 1-SD higher
log-hsTnT was associated with a 58% (95% CI 42%77%)
higher risk of HF after adjusting for classic risk factors
Fig. 1. Kaplan-Meier curves illustrating heart failure (HF)free survival by tertiles of hsTnT in (a) those without and (b) those with base-
line coronary heart disease. Blue curves are the lowest tertile (9.7 ng/L), red the middle tertile (9.814.2 ng/L), and green the highest ter-
tile (14.3 ng/L). Cutoffs are defined from the whole cohort.
Troponin Tand Incident Heart Failure  Welsh et al 233(model 3; Table 2), and this was attenuated to a 34% higher
risk (95% CI 19%52%) after adjusting for NT-proBNP as
well (model 4). A test for interaction between the risk of
HF associated with baseline hsTnT concentration and base-
line CHD status was not significant: P = .32; Fig 2). Indeed,
there was no evidence that level of any risk factor modified
the association between hsTnT and risk of HF (Fig 2).Prediction of HF
Of the 121 men with a baseline hsTnT <5 ng/L (the
assay limit of detection), only 1 developed new-onset HF
(0.8%, 95% CI 0%3.8%), compared with 294 of the 3731
with detectable hsTnT (7.9%, 95% CI 7.1%8.8%). This
corresponds to a sensitivity of 99.7% (95% CI
98.1%99.9%) and a specificity of 3.4% (95% CI
2.8%4.0%). Only 35 participants had an NT-proBNP
below the limit of detection (5 pg/mL), and none of those
developed HF during follow-up.
An HF risk score based on classic risk factors (without
sex or race) yielded a C-index of 0.730 (model A; Table 3).
Addition of NT-proBNP improved the C-index substan-
tially to 0.791 (model B). However, further addition ofTable 2. Associations of hsTnT (Per SD Inc
Study/Events N (n events)
Model 1 Mo
HR (95% CI) P Value HR (95% C
All participants 3852 (295) 1.81 (1.661.97) <.001 1.64 (1.471
Participants without
baseline CHD
3165 (201) 1.76 (1.571.96) <.001 1.59 (1.401
Participants with
baseline CHD
687 (94) 1.82 (1.552.12) <.001 1.79 (1.472
Model 1: unadjusted. Model 2: adjusted for age, total cholesterol, HDL choles
pressure medication use, statin use, and myocardial infarction that occurred durin
activity, FEV1, alcohol use, atrial fibrillation, and CRP. Model 4: additionally adju
HR, hazard ratio; other abbreviations as in Table 1.hsTnT (model C) did not further improve prediction
(C-index 0.794). A model based on age and NT-proBNP
only (model D) yielded a C-index of 0.757 and was almost
as good at discriminating HF events as any of the other,
more complex, models.
With the use of other prediction metrics, adding hsTnT to
a model containing NT-proBNP (models C vs B) did not
improve the continuous NRI (+6.7%, 95% CI ¡4.9 to
16.0%; P = .26), although there was a slight improvement
in the IDI (+0.013, 95% CI 0.0030.026; P = .006). Data
were similar when stratified by baseline CHD (data not pre-
sented).Discussion
In this cohort of older British men, hsTnT was consis-
tently strongly associated with incident HF, suggesting that
subclinical myocardial damage may be an important risk
factor for HF, even in individuals without diagnosed CHD.
HF rarely occurred during 12.6 years of follow-up (0.8%
incidence, 95% CI 0%3.8%) in men who had a baseline
hsTnT below the limit of detection (5 ng/L). As such, these
data raise mechanistic questions regarding the source ofrease on Log Scale) With Heart Failure
del 2 Model 3 Model 4
I) P Value HR (95% CI) P Value HR (95% CI) P Value
.82) <.001 1.58 (1.421.77) <.001 1.34 (1.191.52) <.001
.81) <.001 1.51 (1.321.74) <.001 1.33 (1.151.53) <.001
.18) <.001 1.83 (1.482.26) <.001 1.44 (1.131.84) .001
terol, systolic blood pressure, IMD, BMI, smoking, diabetes, eGFR, blood
g follow-up. Model 3: additionally adjusted for heart rate, glucose, physical
sted for NT-proBNP. CHD, coronary heart disease; CI, confidence interval;
Fig. 2. Hazard ratios (with 95% confidence intervals [CIs]) for heart failure per 1 SD increase in hsTnT, stratified by a range of other risk
factors. P values are tests for interaction comparing the effect of hsTnT in stratified groups. CHD, coronary heart disease; NT-proBNP,
N-terminal proB-type natriuretic peptide; BMI, body mass index; SBP, systolic blood pressure; CRP, C-reactive protein; eGFR, estimated
glomerular filtration rate.
234 Journal of Cardiac Failure Vol. 25 No. 4 April 2019troponin elevation in apparently healthy men, and how
pathologies that raise troponin might be associated with
increased HF risk. Although useful in predicting HF when
added to conventional risk factors, TnT did not improve HF
prediction when added to NT-proBNP.Table 3. Prediction of Heart Failure in Those Without Baseline Corona
With and Without hs
Model C-index vs Model A
Model A: classic risk factors* 0.730 (0.7010.759)
Model B: classic risk factors*
plus NT-proBNP
0.791 (0.7660.816) +0.061 (0.0390
P < .001
Model C: classic risk factors*
plus NT-proBNP and hsTnT
0.794 (0.7690.819) +0.064 (0.0430
P < .001
Model D: age and NT-proBNP 0.757 (0.7290.785) +0.027 (¡0.004 to
P = .09
Abbreviations as in Table 1.
*Classic risk factors: Age, total cholesterol, HDL cholesterol, systolic blood pre
statin use, heart rate, glucose, physical activity, FEV1, alcohol use, atrial fibrillatioHF Prediction
One of the reasons NT-proBNP is such an attractive and
powerful biomarker in CVD prediction in general17,21,22 is
that it integrates information from several importantry Heart Disease: C-Statistics Matrix Comparing Various Models
TnT (n = 3852)
vs Model B vs Model C
.082)
.086) +0.004 (¡0.003 to 0.010)
P = .28
0.058) ¡0.034 (¡0.050 to ¡0.018)
P < .001
¡0.037 (¡0.055 to ¡0.020)
P < .001
ssure, IMD, BMI, smoking, diabetes, eGFR, blood pressure medication use,
n, and baseline cardiovascular disease.
Troponin Tand Incident Heart Failure  Welsh et al 235pathophysiologic pathways. As well as reflecting cardiac
overload, NT-proBNP is a marker of myocardial ischemia,
therefore overlapping with troponin.23,24 Circulating levels
of both NT-proBNP and hsTnT probably also reflect renal
function.25 Despite this, we still found a moderate associa-
tion between hsTnT and HF, even after adjusting for classic
risk factors and NT-proBNP. However, once NT-proBNP is
included in a model for HF prediction, the baseline C-statis-
tic is already high (0.79) and is therefore difficult to
improve upon. Data from the ARIC (Atherosclerosis Risk
in Communities) study showed that when TnT was added
to a range of classic risk factors plus NT-proBNP, the
C-index for HF prediction was improved statistically signif-
icantly, but only clinically modestly (by +0.014 in men and
+0.012 in women).9 Although the present study is smaller
in size, our data broadly agree with those of ARIC: if hsTnT
does predict HF beyond NT-proBNP, the discrimination
gained is very moderate. Our data also advance findings
from studies of patients with established acute and chronic
HF. For example, in chronic HF patients in the RED-HF
(Reduction of Events by Darbepoetin Alfa in Heart Failure)
trial, among a range of cardiac biomarkers only hsTnT
added to NT-proBNP in the prediction of adverse out-
come.26 In the MARATHON (Multicentre Australian Risk
Algorithm to Predict Heart Failure Readmission) study,
comprising patients hospitalized with preserved or reduced
ejection fraction HF, elevated troponin I predicted 30-day
readmission to hospital or death, both individually and as
part of a panel of variables.27 Therefore, elevated troponin
appears to be a predictor of adverse outcomes in the pre-
symptomatic, chronic, and acute phases of HF.Mechanisms Linking Troponin and HF
In line with these being older men, the median base-
line hsTnT level in this cohort was »12 ng/L (the 99th
percentile in the healthy population is 14 ng/L) and was
only slightly higher in those with clinically identified
baseline CHD. CHD is the most obvious cause of ele-
vated troponin, although only a minority of our partici-
pants had diagnosed CHD at baseline. However, even in
the absence of a diagnosis of CHD, the prevalence of
subclinical coronary disease was probably high in the
older British men we studied. In addition, other poten-
tially undiagnosed cardiac conditions, such as left ven-
tricular hypertrophy and atrial fibrillation, may cause
myocardial ischemia. Hypertension, diabetes, and
chronic kidney disease (which frequently coexist) lead
to the development of left ventricular hypertrophy and
atrial fibrillation, as well as coronary microvascular dys-
function, which also may raise troponin. Hypertension,
diabetes, and chronic kidney disease, left ventricular
hypertrophy, atrial fibrillation, and coronary microvascu-
lar dysfunction are also predictors (along with those
measured in this study) and precursors of HF. Moreover,
those developing HF had a higher baseline NT-proBNP
concentration, suggesting preexisting myocardial and/orrenal dysfunction. Other noncardiac pathologies, includ-
ing chronic inflammatory disorders, also are associated
with myocardial injury, and the higher baseline CRP in
individuals experiencing incident HF is consistent with
this pathophysiologic connection as well.28 Thus, there
are mechanisms that might explain why troponin is asso-
ciated with incident HF in those without diagnosed
CHD. Many of these factors were taken into account in
our statistical analysis. Future studies should investigate
specifically the ability of troponin measurements to pre-
dict onset of nonischemic dilated cardiomyopathy.
It may be possible to detect subclinical myocardial injury
early and to intervene to reduce the risk of HF. This might be
achieved with the use of the measurement of troponin, NT-
proBNP, or both to diagnose such patients and thereby target
therapy to those at highest risk of HF. Interventions that might
be effective include antihypertensive therapies, antiischemic
therapies, lipid-lowering treatments, antithrombotic therapy,
and, possibly, drugs improving metabolic status (eg, treat-
ments for diabetes and obesity). The small but statistically
significant effect of statins in reducing the risk of incident
HF, independently from MI, is consistent with this hypothe-
sis.29 A recent example of a hypotensive agent which also
lowers troponin is sacubitril/valsartan (formerly LCZ696).30
Prevention of myocardial injury to reduce risk of HF in later
life is therefore an important public health aim, in the same
way that reduction in acute MI and stroke is.Study Strengths and Limitations
Strengths of the study include the prospective nature of
the data and the relatively large size of the study with a
long follow-up period. We used a high-quality validated
clinical assay in routine use in clinical biochemistry depart-
ments to measure both NT-proBNP and hsTnT.
Weaknesses include the findings being based on doctor-
diagnosed HF, and although diagnoses were usually sup-
ported by evidence from hospital investigations, there is
likely to be some outcome misclassification, including
underreporting of incident HF. Because we did not have
echocardiographic data, we were unable to differentiate
incident HF with reduced ejection fraction from HF with
preserved ejection fraction. Similarly, routine coronary
angiography was not performed, in common with most
cohort studies. These limitations mean that we can not be
sure to what extent information gained from measuring
hsTnT overlaps with information that have might been
available had other diagnostic investigations been per-
formed. However, a potential use of cardiac biomarkers is
to select the most appropriate patients in which to carry
out these investigations.31,32 Finally, we studied older
male survivors from a socioeconomically representative
general cohort study, but participants were a predomi-
nantly white population of European origin, so that the
results can not be generalized directly to women, younger
individuals, or other ethnic groups. However, additional
studies, such as ARIC (ages 4564 y at baseline),9 also
236 Journal of Cardiac Failure Vol. 25 No. 4 April 2019demonstrated an association of hsTnT with incident HF in
both men and women in an ethnically diverse cohort, pro-
viding external validity.Conclusions
Although NT-proBNP is the most powerful predictor of
HF, even low-grade elevation of hsTnT is consistently asso-
ciated with a higher risk of HF in older men, and HF rarely
occurs when hsTnT is near the limit of detection. Interven-
tions to prevent myocardial injury may mitigate risk of HF
in later life.Disclosures
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